1. Home
  2. NIU vs ACTU Comparison

NIU vs ACTU Comparison

Compare NIU & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NIU
  • ACTU
  • Stock Information
  • Founded
  • NIU 2014
  • ACTU 2015
  • Country
  • NIU China
  • ACTU United States
  • Employees
  • NIU N/A
  • ACTU N/A
  • Industry
  • NIU Auto Manufacturing
  • ACTU
  • Sector
  • NIU Consumer Discretionary
  • ACTU
  • Exchange
  • NIU Nasdaq
  • ACTU NYSE
  • Market Cap
  • NIU 141.2M
  • ACTU 153.1M
  • IPO Year
  • NIU 2018
  • ACTU 2024
  • Fundamental
  • Price
  • NIU $1.85
  • ACTU $8.98
  • Analyst Decision
  • NIU
  • ACTU
  • Analyst Count
  • NIU 0
  • ACTU 0
  • Target Price
  • NIU N/A
  • ACTU N/A
  • AVG Volume (30 Days)
  • NIU 511.5K
  • ACTU 60.5K
  • Earning Date
  • NIU 11-18-2024
  • ACTU 11-13-2024
  • Dividend Yield
  • NIU N/A
  • ACTU N/A
  • EPS Growth
  • NIU N/A
  • ACTU N/A
  • EPS
  • NIU N/A
  • ACTU N/A
  • Revenue
  • NIU $420,244,416.00
  • ACTU N/A
  • Revenue This Year
  • NIU $31.46
  • ACTU N/A
  • Revenue Next Year
  • NIU $29.83
  • ACTU N/A
  • P/E Ratio
  • NIU N/A
  • ACTU N/A
  • Revenue Growth
  • NIU 5.83
  • ACTU N/A
  • 52 Week Low
  • NIU $1.57
  • ACTU $5.51
  • 52 Week High
  • NIU $3.50
  • ACTU $10.16
  • Technical
  • Relative Strength Index (RSI)
  • NIU 37.37
  • ACTU N/A
  • Support Level
  • NIU $1.75
  • ACTU N/A
  • Resistance Level
  • NIU $2.03
  • ACTU N/A
  • Average True Range (ATR)
  • NIU 0.12
  • ACTU 0.00
  • MACD
  • NIU -0.04
  • ACTU 0.00
  • Stochastic Oscillator
  • NIU 19.67
  • ACTU 0.00

About NIU Niu Technologies

Niu Technologies designs, manufactures and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycle, moped and bicycle series, including the NQi, MQi, UQi, F series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.

About ACTU ACTUATE THERAPEUTICS INC

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Share on Social Networks: